US2936024056 - Common Stock
ENSYSCE BIOSCIENCES INC
NASDAQ:ENSC (4/29/2024, 1:36:55 PM)
0.6
+0.02 (+3.45%)
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 7 full-time employees. The company went IPO on 2017-12-01. The firm is engaged in developing solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. The firm is using its proprietary technology platforms to develop safer prescription drugs. The firm's development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology - the Trypsin Activated Abuse Protection, (the TAAP platform), and an over-dose protection opioid prodrug technology - the Multi-Pill Abuse Resistant, (MPAR platform). The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform when combined with the Company’s TAAP prodrugs is designed not only to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences.
ENSYSCE BIOSCIENCES INC
7946 Ivanhoe Avenue, Suite 201
La Jolla CALIFORNIA
P: 18582634196
CEO: Daniel B. Silvers
Employees: 7
Website: https://ensysce.com/
Fisker stock is on the move Monday as FSR investors learn about the EV company securing an additional $150 million in funding.
ENSC stock results show that Ensysce Biosciences missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ensysce Biosciences (NASDAQ:ENSC) just reported results for the fourth quarter ...
Ensysce Biosciences (ENSC) experienced a 4% drop in premarket trading as the biotech announced agreements for the immediate exercise of outstanding...
Ensysce (ENSC) stock closed 22% higher Tuesday after the company said it had received FDA breakthrough therapy designation for its overdose-resistant opioid drug candidate.
Ensysce Biosciences files for a prospectus regarding the sale of its common stock and common warrants, but notes that it is not an offer to sell these...
Here you can normally see the latest stock twits on ENSC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: